The Latest Breaking News from Pfizer

To better weather future pandemics, the way countries procure vaccines needs to change radically

COVID vaccines are very effective, but for some groups they don’t generate as strong an immune response. These groups include older adults and people with weakened immune systems, for example due to cancer or other medical conditions. They tend to already be at heightened risk from COVID.

Sanofi said Friday its shot significantly reduced the risk of babies becoming hospitalized with RSV. But Sanofi stock dipped Friday.

The U.S. Food and Drug Administration approved the world’s first vaccine to prevent the respiratory infection RSV, short for respiratory syncytial virus, on May 3, 2023. The new shot represents six decades of starts and stops in the hunt for a vaccine to curb one of the most common winter…

Artificial intelligence can shave years off the development process, and companies like Japan’s Takeda are making large investments.

'Process of making both varenicline and cytisine available feels excruciatingly slow'

The FDA has approved the first vaccine for respiratory syncytial virus (RSV).

When so much time and effort goes into developing the best medical treatments, we expect them to be available when we need them. The same goes for addiction treatments, so it’s worrying that two of the most effective drugs for quitting smoking aren’t available in the UK.

After decades of failure in the quest for an RSV vaccine, doctors are anxious to finally have something to offer — especially after a virus surge that strained hospitals last fall.

GSK's RSV vaccine is approved for people aged 60 and older.

GSK stock jumped Wednesday after the drugmaker won the first-ever approval for an RSV vaccine, leading rivals Pfizer and Moderna.